Langer R. Drug delivery and targeting. Nature. 1998;392:5–10.

CAS  PubMed  Google Scholar 

Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–22.

Article  CAS  PubMed  Google Scholar 

Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.

Article  Google Scholar 

Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660–8.

Article  CAS  PubMed  Google Scholar 

Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974;1:1313–6.

Article  CAS  PubMed  Google Scholar 

Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10:853–8.

Article  PubMed  Google Scholar 

Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs. 2011;71:2531–58.

Article  CAS  PubMed  Google Scholar 

Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.

Article  CAS  PubMed  Google Scholar 

Akhtar N, Mohammed SA, Singh V, Abdellatif AA, Mohammad HA, Ahad A, et al. Liposome-based drug delivery of various anticancer agents of synthetic and natural product origin: a patent overview. Pharm Pat Anal. 2020;9:87–116.

Article  CAS  PubMed  Google Scholar 

Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1:297–315.

CAS  Google Scholar 

Maiti P. Drug-delivery vehicles and their efficiency toward cancer treatment. Nanomed (Lond). 2020;15:1637–40.

Article  CAS  Google Scholar 

Kita K, Dittrich C. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug–carrier interactions. Expert Opin Drug Deliv. 2011;8:329–42.

Article  CAS  PubMed  Google Scholar 

Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19:566–75.

Article  CAS  PubMed  Google Scholar 

Gerecke C, Edlich A, Giulbudagian M, Schumacher F, Zhang N, Said A, et al. Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes. Nanotoxicology. 2017;11:267–77.

Article  CAS  PubMed  Google Scholar 

Park H, Park K. Biocompatibility issues of implantable drug delivery systems. Pharmacol Res. 1996;13:1770–6.

Article  CAS  Google Scholar 

Tang Y, Wang X, Li J, Nie Y, Liao G, Yu Y, et al. Overcoming the reticuloendothelial system barrier to drug delivery with a “Don’t-Eat-Us” strategy. ACS Nano. 2019;13:13015–26.

Article  CAS  PubMed  Google Scholar 

Liu X, Tang I, Wainberg ZA, Meng H. Safety considerations of cancer nanomedicine—a key step toward translation. Small. 2020;16:e2000673.

Article  PubMed  PubMed Central  Google Scholar 

Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, et al. Nanomedicinal products: a survey on specific toxicity and side effects. Int J Nanomed. 2017;12:6107–29.

Article  CAS  Google Scholar 

Caracciolo G. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine. 2015;11:543–57.

Article  CAS  PubMed  Google Scholar 

Zahednezhad F, Saadat M, Valizadeh H, Zakeri-Milani P, Baradaran B. Liposome and immune system interplay: challenges and potentials. J Control Release. 2019;305:194–209.

Article  CAS  PubMed  Google Scholar 

Onishchenko N, Tretiakova D, Vodovozova E. Spotlight on the protein corona of liposomes. Acta Biomater. 2021;134:57–78.

Article  CAS  PubMed  Google Scholar 

Yang K, Reker-Smit C, Stuart MCA, Salvati A. Effects of protein source on liposome uptake by cells: Corona composition and impact of the excess free proteins. Adv Health Mater. 2021;10:e2100370.

Article  Google Scholar 

Moghimi SM, Hamad I. Liposome-mediated triggering of complement cascade. J Liposome Res. 2008;18:195–209.

Article  CAS  PubMed  Google Scholar 

Yan X, Scherphof GL, Kamps JA. Liposome opsonization. J Liposome Res. 2005;15:109–39.

Article  CAS  PubMed  Google Scholar 

Clogston JD. The importance of nanoparticle physicochemical characterization for immunology research: what we learned and what we still need to understand. Adv Drug Deliv Rev. 2021;176:113897.

Article  CAS  PubMed  Google Scholar 

Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, et al. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017;519:1–10.

Article  CAS  PubMed  Google Scholar 

Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXILI/CAELYXI) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870–7.

Article  CAS  PubMed  Google Scholar 

Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209–18.

Article  CAS  PubMed  Google Scholar 

DOXIL® (doxorubicin HCl liposome injection) for intravenous infusion, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf (2007).

Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475–80.

Article  CAS  PubMed  Google Scholar 

Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D. PEGylated liposomes accumulate in the areas relevant to skin toxicities via passive extravasation across “Leaky” Endothelium. ACS Nano. 2022;16:6349–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151:201–15.

Article  CAS  PubMed  Google Scholar 

Chu Y, Tang W, Zhang Z, Li C, Qian J, Wei X, et al. Deciphering protein Corona by scFv-based affinity chromatography. Nano Lett. 2021;21:2124–31.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Chu Y, Li C, Tang W, Qian J, Wei X, et al. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. J Control Release. 2021;330:493–501.

Article  CAS  PubMed  Google Scholar 

Tang W, Zhang Z, Li C, Chu Y, Qian J, Ying T, et al. Facile separation of PEGylated liposomes enabled by anti-PEG scFv. Nano Lett. 2021;21:10107–13.

Article  CAS  PubMed  Google Scholar 

Choi WG, Kim DK, Shin Y, Park R, Cho YY, Lee JY, et al. Liquid chromatography-tandem mass spectrometry for the simultaneous determination of doxorubicin and its metabolites doxorubicinol, doxorubicinone, doxorubicinolone, and 7-deoxydoxorubicinone in mouse plasma. Molecules. 2020;25:1254.

Wei X, Shamrakov D, Nudelman S, Peretz-Damari S, Nativ-Roth E, Regev O, et al. Cardinal role of intraliposome doxorubicin-sulfate nanorod crystal in doxil properties and performance. ACS Omega. 2018;3:2508–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.

Article  CAS  PubMed  Google Scholar 

Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88:10661–6.

Article  CAS  PubMed  Google Scholar 

Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol. 2016;138:1712–5.